Matthew Ku

25PUBLICATIONS
193CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Immunogenetics (incl. genetic immunology)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Allergy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Jun 11, 2026
High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

|Jun 10, 2026
Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO.

|Apr 14, 2026
Historical outcomes for patients with stage IA NLPHL: Global NLPHL One Working Group retrospective analyses.

Jamie E Flerlage, Dennis A Eichenauer, Michael Fuchs

|Feb 05, 2026
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter transformation.

Katharine Louise Lewis, Sarit E Assouline, Ross Ian Baker

|Jan 07, 2026
Impact of prior bendamustine exposure on bispecific antibody outcomes in relapsed/refractory follicular lymphoma.

Gloria Iacoboni, Emil Ramsø Kyvsgaard, Víctor Navarro Garcés

|Jun 18, 2025
Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study.

Adrian Minson, Emma Verner, Pratyush Giri

Pageof 5

Frequent Collaborators

12 joint publications

Chan Yoon Cheah

12 joint publications

Nada Hamad

8 joint publications

Michael J Dickinson

6 joint publications

Eliza A Hawkes